JNJ-0387 / J&J - LARVOL DELTA

A Study of JNJ-87890387 for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Apr 2028 ➔ Jul 2028

Trial completion date • Solid Tumor

A Study of JNJ-87890387 for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=158 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Dec 2027 ➔ Apr 2028

Trial completion date • Solid Tumor

Extending ENPP3 expression inference from tissue microarrays to whole tissue sections: building a case for automated patient enrichment and IHC scoring (AACR 2025) - P1 | "An ongoing Phase I study (NCT06178614) is evaluating the safety and preliminary anti-tumor activity of ENPP3xCD3 (JNJ-87890387) in ENPP3-unselected, advanced-stage solid tumors with a high prevalence of ENPP3 expression...This approach could (1) help reduce the number of patients requiring IHC assessment and (2) minimize pathologists' scoring workload, thus reducing trial costs and expediting patient enrollment. Our results suggest that (3) TMA cores may contain sufficient signal to train models for deployment on WTS for some tasks, which could help minimize modeling costs."

Clinical • Patient Enrichment • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of JNJ-87890387 for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=158 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Mar 2027 ➔ Dec 2027

Trial completion date • Oncology • Solid Tumor

A Study of JNJ-87890387 for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Sep 2026 ➔ Mar 2027 | Trial primary completion date: Sep 2026 ➔ Mar 2027

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

JNJ-87890387, a novel ENPP3 bispecific T-cell redirector (ENPP3xCD3) with tumor selectivity through targeting apical surface antigens (AACR 2024) - "In vivo, JNJ-87890387 demonstrated ENPP3-expression-dependent potent anti-tumor activity in multiple cell line-derived and patient tumor-derived RCC and HCC xenograft models with complete tumor regressions, and evidence of dose-dependent CD4+ and CD8+ T cell infiltration into the tumors. Preclinical safety assessment in the cynomolgus monkey with a tool molecule using the therapeutic ENPP3 binding arm but with a cynomolgus CD3 cross-reactive arm only identified toxicities consistent with the modality.In summary, these data support JNJ-87890387's clinical development with an ongoing first-in-human Phase I study to evaluate the safety and preliminary anti-tumor activity in advanced-stage solid tumors with a high prevalence of ENPP3 expression."

Late-breaking abstract • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • CD4 • CD8

A Study of JNJ-87890387 for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Janssen Research & Development, LLC

Metastases • New P1 trial • Oncology • Solid Tumor